WoundReference improves clinical decisions
 Choose the role that best describes you
Jodheea-Jutton A, Hindocha S, Bhaw-Luximon A, et al.
Foot (Edinburgh, Scotland). Date of publication 2022 Sep 1;volume 52():101909.
1. Foot (Edinb). 2022 Sep;52:101909. doi: 10.1016/j.foot.2022.101909. Epub 2022 Feb 4. Health economics of diabetic foot ulcer and recent trends to accelerate treatment. Jodheea-Jutton A(1), Hindocha S(2), Bhaw-Luximon A(3). Author information: (1)Department of Medicine, University of Mauritius, 80837 Réduit, Mauritius; Biomaterials, Drug Delivery and Nanotechnology Unit, Center for Biomedical and Biomaterials Research, University of Mauritius, 80837 Réduit, Mauritius. (2)Department of Plastic and Reconstructive Surgery, Bedford Hospital NHS Trust, Kempston Road, Bedford, MK42 FDJ, United Kingdom. (3)Biomaterials, Drug Delivery and Nanotechnology Unit, Center for Biomedical and Biomaterials Research, University of Mauritius, 80837 Réduit, Mauritius. Electronic address: a.luximon@uom.ac.mu. Diabetic foot ulcer is a preventable complication of diabetes that imposes a significant burden on the community. It leads to amputation and increased disability if left untreated and thus bears profound implications on the individual, the community and the health system at large. Diabetic foot (DF) is an area of research interest where interdisciplinary researchers are trying to elucidate the best strategy to halt the progression of chronic diabetic wounds. It is an area where tissue engineering research is making a strong impact through the use of scaffolds and skin substitutes for diabetic wound healing. This review aims at discussing the geographical health economics, its impact on healing and factors influencing financial costs of DFU. The upcoming economic and clinical impacts due to disease outbreak such as the 2020 COVID-19 has also been discussed. Finally, it will discuss novel therapy available with emphasis on skin tissue engineering scaffolds with a cost-benefit analysis. The review aims at promoting better management of people with diabetes with emphasis on emerging treatments and technologies. Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved. DOI: 10.1016/j.foot.2022.101909 PMID: 36049265 [Indexed for MEDLINE]
Appears in following Topics:
HBO Treatment Emerging Indication: Long COVID
t
-->